Today’s big question for investors is, “what’s going on with Atara Biotherapeutics, Inc. (NASDAQ:ATRA) stock? Its price is jumping 0.37 points, trading at $14.2 levels, and is up 2.68% from its previous close of $13.83. The shares seem to have an active trading volume day with a reported 206997 contracts so far this session. ATRA shares had a relatively better volume day versus average trading capacity of 705.71 thousand shares, but with a 53.08 million float and a -1.28% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ATRA stock indicates that the average analyst price target is $29.13 per share. This means the stock has a potential increase of 105.14% from where the ATRA share price has been trading recently which is between $13.27 and $13.875.
During the recent trading session for Atara Biotherapeutics, Inc. (NASDAQ:ATRA), the company witnessed their stock rise $0.32 over a week and surge $1.55 from the price 20 days ago. When compared to their established 52-week high of $43.93, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 11/12/18. The recent low of $10.38 stood for a -67.68% since 10/31/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.04 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Atara Biotherapeutics, Inc., the two-week RSI stands at 57.17. This figure suggests that ATRA stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current ATRA readings is similarly very revealing as it has a stochastic reading of 61.37% at this stage. This figure means that ATRA share price today is being neutral.
Technical chart claims that Atara Biotherapeutics, Inc. (ATRA) would settle between $14.05/share to $14.26/share level. However, if the stock price goes below the $13.44 mark, then the market for Atara Biotherapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $13.05 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.06. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at JP Morgan lowered their recommendation on shares of ATRA from Overweight to Neutral in their opinion released on November 08. Goldman analysts have lowered their rating of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) stock from Neutral to Sell in a separate flash note issued to investors on September 27. Analysts at Jefferies lowered the stock to a Hold call from its previous Buy recommendation, in a research note that dated back to September 16.
ATRA equity has an average rating of 2.27, with the figure leaning towards a bullish end. 9 analysts who tracked the company were contacted by Reuters. Amongst them, 3 rated the stock as a hold while the remaining 6 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while others rated it as a sell. 5 analysts rated Atara Biotherapeutics, Inc. (NASDAQ:ATRA) as a buy or a strong buy while 1 advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.